for the FAIR-HF Trial Investigators * Members of the Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) study group are listed in the Appendix.
2/28/2019 · The 2009 Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) trial assessed whether the administration of IV ferric carboxymaltose versus placebo in 459 patients with symptomatic HFrEF (defined as LVEF ?40% with NYHA II-III symptoms or LVEF ?45% with NYHA III symptoms) and concomitant iron deficiency (ferritin <100 ug/L or ferritin 100-299 ug/L with.Deficiency and Chronic Heart Failure (FAIR-HF) trial, to determine whether the correction of iron deficiency with the use of intravenous iron (ferric carboxymaltose) confers symptomatic benefits in, Methods and results: FAIR-HF randomized 459 patients with CHF [NYHA class II or III, LVEF ?40% (NYHA II) or ?45% (NYHA III)] and ID to i.v. iron as ferric carboxymaltose (FCM) or placebo in a 2:1 ratio. We analysed the efficacy and safety according to the presence or absence of anaemia (haemoglobin ?120 g/L) at baseline.5/15/2020 · The FAIR-HF trial demonstrated that IV iron therapy in patients with CHF and ID improves their functional status and increases haemoglobin in those that were also anaemic. [ 16], 5/30/2010 · FAIR-HF was the first double blind placebo control trial to be undertaken exploring whether intravenous iron benefited patients with CHF. “Prior to FAIR-HF blinding the studies had proved difficult because i.v. iron is a black solution. FAIR-HF got round this difficulty by delivering the iron in blacked out syringes,” explained Ponikowski.6/6/2020 · After the positive findings of the FAIR-HF trial , there is a need for cardiologists to study the iron metabolism of patients with CHF, and it seems reasonable to undertake a work-up evaluation if ...
